The Role of Volatile Organic Compounds (VOCs), Airway Mucins and Microbiome in the Development of Bronchopulmonary Dysplasia and the Feasibility of Exhaled Breath VOCs Analysis as an Early Detection Tool

Status: Recruiting
Location: See location...
Intervention Type: Other, Diagnostic test
Study Type: Observational
SUMMARY

Bronchopulmonary dysplasia (BPD), the most common respiratory complication of extremely preterm birth, significantly impacts healthcare with high morbidity and mortality rates. Despite the well-established primordial role of inflammation and oxidative stress in the development of BPD, clinical practice does not incorporate the testing for biomarkers associated with the development of BPD. The diagnosis of BPD based on required respiratory support at 36 weeks PML, stresses the need for an early prediction tool which could identify patients with high levels of these biomarkers. This on its turn, could also improve treatment approaches in clinical practice which are currently mostly supportive or non-specific and do not target underlying pathophysiologic pathways. Secondly, mucin expression aim to play a rol in other respiratory diseases, whereas in BPD only the potential role of MUC1 was explored. Thirdly, the composition of the airway microbial composition of an infant is assumed to be influenced by different factors. From early on in pregnancy the airway microbiome of the infant is formed, offering a protective role against pathologies. On the other hand, the role of the airway microbiome in the development of BPD remains unclear and needs to be elucidated. The threefold aim of this study is as follows: I. The development of a non-invasive breath test that allows early detection of bronchopulmonary dysplasia, using the potential of VOCs in exhaled breath as biomarkers for inflammation and oxidative stress. II. The exploration of the composition and diversity of the airway microbiome in infants with BPD, their association with exhaled VOCs and the exploration of the placental and vaginal microbiome. III. The detection of potential alterations in airway mucin expression in BPD patients. Through this comprehensive approach, we seek to gain a deeper understanding of how these mutual associations may contribute to the later development of BPD. In total 140 preterm infants, including 70 BPD patients and 70 preterm controls, born below 30 weeks' gestation at the Antwerp University Hospital will be included.

Eligibility
Participation Requirements
Sex: All
Maximum Age: 3 days
Healthy Volunteers: t
View:

• Born at a gestational age \< 30 weeks

Locations
Other Locations
Belgium
University Hospital Antwerp
RECRUITING
Edegem
Contact Information
Primary
Inès Ghys, MD
ines.ghys@uantwerpen.be
+3232655230
Backup
Kristien Vanhaverbeke, MD, PhD
Time Frame
Start Date: 2024-06-14
Estimated Completion Date: 2027-09
Participants
Target number of participants: 140
Treatments
Preterm infants
all included infants will undergo a breath test and two throat swabs, in case the infant is intubated also endotracheal aspirates will be collected
Mothers of preterm infants
placental biopsies, a placental swab and a vaginal swab will be taken after birth
Sponsors
Leads: University Hospital, Antwerp

This content was sourced from clinicaltrials.gov